Results 81 to 90 of about 176 (130)
BACKGROUND: Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 oncogene (t(9;22)) and typically presents in a chronic phase (
Baan Abdulatif Mtashar +1 more
doaj +1 more source
We report the case of a 51-year-old male patient initially diagnosed with JAK2-V617F-mutated polycythemia vera (PV), who developed chronic phase BCR::ABL1-positive chronic myeloid leukemia (CML) 11 years later.
Paride Bartolucci +7 more
doaj +1 more source
Philadelphia Chromosome-negative, bcr/abl-positive Chronic Myelogenous Leukemia.
Inokuchi, Koiti, Dan, Kazuo
openaire +3 more sources
Seventy months after diagnosis, minimal residual disease is undetectable in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in long-lasting continuous cytogenetic conversion (CCC), achieved through alpha 2a-interferon ...
S Pardini +7 more
doaj
Selective Induction of Apoptosis in Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Cells by an Inhibitor of BCR–ABL Tyrosine Kinase, CGP 57148 [PDF]
The BCR - ABL tyrosine kinase has been implicated as the cause of Philadelphia chromosome (Ph1)-positive leukemias. We report herein that CGP 57148, a selective inhibitor of the ABL tyrosine kinase, caused apoptosis specifically in bcr - abl-positive chronic myelogenous leukemia (CML) cells, K562 and KYO-1.
Shingo Dan, Takashi Tsuruo
exaly +3 more sources
Abstract Nilotinib, an orally bioavailable, selective Bcr-Abl tyrosine kinase inhibitor, is 30-fold more potent than imatinib in pre-clinical models, and overcomes most imatinib resistant BCR-ABL mutations. In this phase 2 open-label study, 400 mg nilotinib was administered orally twice daily to 280 patients with Philadelphia ...
Kapil Bhalla +2 more
exaly +5 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Experimental Hematology, 2000
An important step in successful autografting of patients with chronic myelogenous leukemia is the delivery of a leukemia-free graft. We conducted this study to determine whether the cytogenetic response after autografting was correlated with the number of BCR ABL-positive cells present within the stem cell grafts.By BCR-ABL mRNA quantification, we ...
M T, Corsetti +12 more
openaire +2 more sources
An important step in successful autografting of patients with chronic myelogenous leukemia is the delivery of a leukemia-free graft. We conducted this study to determine whether the cytogenetic response after autografting was correlated with the number of BCR ABL-positive cells present within the stem cell grafts.By BCR-ABL mRNA quantification, we ...
M T, Corsetti +12 more
openaire +2 more sources
Annals of Hematology, 2008
Assay of phosphotyrosine levels using flow cytometry has been used to identify patients with chronic myelogenous leukemia positive for the Bcr-Abl fusion gene. We hypothesized that clinical monitoring could identify treatment response through reductions in intragranulocyte phosphotyrosine.
Xuemei, Sun +9 more
openaire +2 more sources
Assay of phosphotyrosine levels using flow cytometry has been used to identify patients with chronic myelogenous leukemia positive for the Bcr-Abl fusion gene. We hypothesized that clinical monitoring could identify treatment response through reductions in intragranulocyte phosphotyrosine.
Xuemei, Sun +9 more
openaire +2 more sources

